These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35121075)

  • 1. Inhibition of tumor necrosis factor improves conventional steroid therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis in a cohort of patients.
    Ao S; Gao X; Zhan J; Ai L; Li M; Su H; Tang X; Chu C; Han J; Wang F
    J Am Acad Dermatol; 2022 Jun; 86(6):1236-1245. PubMed ID: 35121075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Combination Therapy With Etanercept and Systemic Corticosteroids for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Multicenter Observational Study.
    Zhang J; Lu CW; Chen CB; Wang CW; Chen WT; Cheng B; Ji C; Chung WH
    J Allergy Clin Immunol Pract; 2022 May; 10(5):1295-1304.e6. PubMed ID: 35131514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute pancreatic injuries: A complication of Stevens-Johnson syndrome/toxic epidermal necrolysis associated with cytotoxic immunocell activation.
    Gao X; Tang X; Ai L; Gao Q; Liao Q; Chen M; Chen X; Zhou H; Ye Y; Li M; Han J; Wang F
    J Am Acad Dermatol; 2021 Mar; 84(3):644-653. PubMed ID: 32561372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor inhibitors enhance corticosteroid therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis linked to immune checkpoint inhibitors: a prospective study.
    He CX; Guo L; Qu T; Jin HZ
    Front Immunol; 2024; 15():1421684. PubMed ID: 39170619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TNF-α induced extracellular release of keratinocyte high-mobility group box 1 in Stevens-Johnson syndrome/toxic epidermal necrolysis: Biomarker and putative mechanism of pathogenesis.
    Nwikue G; Olsson-Brown A; Aboheimed N; Yip V; Jolly C; Luchian A; Ressel L; Sharma A; Bergfeld W; Ahmed S; Dickinson A; Pirmohamed M; Carr DF
    J Dermatol; 2023 Sep; 50(9):1129-1139. PubMed ID: 37269158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic association of IFN-γ +874T/A polymorphism in Mexican patients with drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Charli-Joseph Y; Lima G; Ramos-Bello D; Aguilar D; Orozco-Topete R; Llorente L
    Arch Dermatol Res; 2013 May; 305(4):353-7. PubMed ID: 23224615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the Era of Systems Medicine.
    Chen CB; Wang CW; Chung WH
    Methods Mol Biol; 2022; 2486():37-54. PubMed ID: 35437717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of IL-13, IL-15 and Granulysin in the Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.
    Sadek M; Iqbal O; Siddiqui F; Till S; Mazariegos M; Campbell E; Mudaliar K; Speiser J; Bontekoe E; Kouta A; Farooqui A; Daravath B; Qneibi D; Sadek R; Hoppensteadt D; Fareed J; Bouchard C
    Clin Appl Thromb Hemost; 2021; 27():1076029620950831. PubMed ID: 33560872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review of case-control studies of cytokines in blister fluid and skin tissue of patients with Stevens Johnson syndrome and toxic epidermal necrolysis.
    Stewart TJ; Farrell J; Frew JW
    Australas J Dermatol; 2024 Sep; 65(6):491-504. PubMed ID: 38831709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Hasegawa A; Abe R
    F1000Res; 2020; 9():. PubMed ID: 32595945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etanercept treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Tian CC; Ai XC; Ma JC; Hu FQ; Liu XT; Luo YJ; Tan GZ; Zhang JM; Li XQ; Guo Q; Zeng FQ; Shi ZR; Wang L
    Ann Allergy Asthma Immunol; 2022 Sep; 129(3):360-365.e1. PubMed ID: 35598882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. APOA4 as a novel predictor of prognosis in Stevens-Johnson syndrome/toxic epidermal necrolysis: A proteomics analysis from two prospective cohorts.
    Gong T; Zhang P; Ruan SF; Xiao Z; Chen W; Lin M; Zhong Q; Luo R; Xu Q; Peng J; Cheng B; Chen F; Chen L; Chung WH; Ji C
    J Am Acad Dermatol; 2023 Jul; 89(1):45-52. PubMed ID: 36963506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review.
    Zhang S; Tang S; Li S; Pan Y; Ding Y
    J Dermatolog Treat; 2020 Feb; 31(1):66-73. PubMed ID: 30702955
    [No Abstract]   [Full Text] [Related]  

  • 14. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures.
    Schneider JA; Cohen PR
    Adv Ther; 2017 Jun; 34(6):1235-1244. PubMed ID: 28439852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging Insights into Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Induced by Immune Checkpoint Inhibitor and Tumor-Targeted Therapy.
    Lin M; Gong T; Ruan S; Lv X; Chen R; Su X; Cheng B; Ji C
    J Inflamm Res; 2024; 17():2337-2351. PubMed ID: 38645875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of interstitial lung disease related to Stevens-Johnson syndrome/toxic epidermal necrolysis overlap with etanercept: A case report and published work review.
    Wang F; Gao X; Chen X; Tang X; Chen H; Han J
    J Dermatol; 2019 Nov; 46(11):1035-1038. PubMed ID: 31436331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corticosteroids in Stevens-Johnson Syndrome/toxic epidermal necrolysis: current evidence and implications for future research.
    Law EH; Leung M
    Ann Pharmacother; 2015 Mar; 49(3):335-42. PubMed ID: 25406459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Caproni M; Torchia D; Schincaglia E; Volpi W; Frezzolini A; Schena D; Marzano A; Quaglino P; De Simone C; Parodi A; Barletta E; Fabbri P
    Br J Dermatol; 2006 Oct; 155(4):722-8. PubMed ID: 16965421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated endocan levels and its association with clinical severity in Stevens-Johnson Syndrome and toxic epidermal necrolysis.
    Syed D; Iqbal O; Mosier M; Mitchell R; Hoppensteadt D; Bouchard C; Fareed J; Gamelli R
    Int Angiol; 2015 Oct; 34(5):483-8. PubMed ID: 25394955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum IL-17 in patients with erythema multiforme or Stevens-Johnson syndrome/toxic epidermal necrolysis drug reaction, and correlation with disease severity.
    Morsy H; Taha EA; Nigm DA; Shahin R; Youssef EMK
    Clin Exp Dermatol; 2017 Dec; 42(8):868-873. PubMed ID: 28940568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.